INTRODUCTION Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone. MATERIALS AND METHODS The aim of this review is to discuss the results from the clinical studies available, examining potential mechanisms of action and patient selection criteria for this treatment option. RESULTS A total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progression without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223. CONCLUSION Although large randomized prospective trials are warranted, steroid switch seems to offer a good option for certain patients treated with abiraterone acetate plus prednisone or prednisolone.

中文翻译：

---

醋酸阿比特龙酯加泼尼松治疗进展后皮质类固醇激素转换。

简介醋酸阿比特龙加泼尼松被批准用于转移性去势抵抗性前列腺癌。有证据表明，在醋酸阿比特龙加泼尼松或泼尼松龙治疗期间进展的患者，类固醇从泼尼松转为地塞米松。材料与方法这篇综述的目的是讨论可得临床研究的结果，研究该治疗方案的潜在作用机理和患者选择标准。结果总共评估了四项研究。在类固醇转换的可能资格标准中，我们发现：醋酸阿比特龙+泼尼松期间PSA进展而无任何放射学或临床进展；没有与CYP-17抑制有关的严重不良事件; 不适合化疗或镭223。